S&P 500
3,319.47-37.54(-1.12%)Nasdaq
10,793.28-116.99(-1.07%)Russell 2000
1,536.78-5.82(-0.38%)
iRhythm Technologies, Inc. (IRTC)
Chart Events
Performance Outlook
| Previous Close | 227.66 |
| Open | 230.81 |
| Bid | 231.62 x 1000 |
| Ask | 231.86 x 800 |
| Day's Range | 226.72 - 241.78 |
| 52 Week Range | 56.24 - 241.82 |
| Volume | 718,805 |
| Avg. Volume | 409,092 |
| Market Cap | 6.687B |
| Beta (5Y Monthly) | 1.79 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -2.46 |
| Earnings Date | Nov 03, 2020 - Nov 09, 2020 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 226.11 |
- GlobeNewswire
iRhythm Technologies Announces NHS Funding After Winning Artificial Intelligence in Health and Care Award
Company selected from over 500 applicants in first-of-its-kind Digital Health Technologies PilotSAN FRANCISCO and LONDON, Sept. 08, 2020 (GLOBE NEWSWIRE) -- iRhythm Technologies (NASDAQ: IRTC), a leading digital health care solutions company focused on the advancement of cardiac care, has today been named a winner of the Artificial Intelligence (AI) in Health and Care Award. The announcement was made by Secretary of State for Health, Matt Hancock at London Tech Week’s Founders Forum HealthTech Summit this morning. A competitive process run by the Accelerated Access Collaborate (AAC) as part of the NHS AI Lab – in partnership with NHSX and the National Institute for Health Research (NIHR) – the award aims to benefit patients by combining the power of artificial intelligence with the expertise of the NHS to improve health and care outcomes.iRhythm will utilise the funding to trial its Zio service in selected sites – comprising trusts, CCG’s and networks – across the UK. Throughout the three-year program, clinical, pathway and economic outcomes will be monitored and evaluated in order to inform any future commissioning decisions around the adoption of Zio within the NHS.Zio by iRhythm is a small, discreet and easy-to-use cardiac monitoring service, used to detect a range of arrhythmias quickly and accurately. The patch-like device can be fitted at home and provides uninterrupted, comprehensive monitoring of a patient’s heartbeats as they go about their daily lives. Underpinned by artificial intelligence, it detects arrhythmias, at the first time of asking, saving lives and ensuring less pressure is placed upon NHS resources.Commenting on the win, Justin Hall, GM and VP EMEA at iRhythm Technologies said, “The UK is home to some of the most cutting-edge, life-changing medical technologies. However, it is still taking years for medical devices to go from clinical trial to wide-spread adoption, meaning neither patients nor practitioners are seeing the many benefits of these innovations. We’re absolutely delighted to have been chosen as part of the pilot to change that.“Around 1.2 million people in the UK are registered with atrial fibrillation, with nearly half a million predicted to have AF undiagnosed. When treating these serious cardiac conditions, accurate and timely diagnoses can mean the difference between life and death. This funding is a step in the right direction in accelerating our Zio service to ensure that people have access to fast, critical care as and when they need it.”Four phases of award are available to support AI solutions from initial feasibility to evaluation within NHS and social care settings. Phase 4 – of which iRhythm has been selected – is intended to identify AI technologies that need more evidence to merit large-scale commissioning or deployment. The AAC will work with NHS sites to support their adoption of these technologies, and stress test and evaluate them within routine clinical or operational pathways to determine their efficacy and accuracy, as well as their clinical and economic impact.The AI in Health and Care Award forms a key part of the AAC’s ambition to establish a globally leading testing infrastructure for healthcare innovation in the UK.About iRhythm Technologies, Inc. iRhythm is a leading digital health care company redefining the way cardiac arrhythmias are clinically diagnosed. The company combines wearable biosensor devices worn for up to 14 days and cloud-based data analytics with powerful proprietary algorithms that distill data from millions of heartbeats into clinically actionable information. The company believes improvements in arrhythmia detection and characterization have the potential to change clinical management of patients.Forward-Looking Statements This news release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 and the Private Securities Litigation Reform Act of 1995, including statements regarding decisions around the adoption of Zio within the NHS and utilization of its resources. Such statements are based on current assumptions that involve risks and uncertainties that could cause actual outcomes and results to differ materially. These risks and uncertainties, many of which are beyond our control, include risks described in the section entitled “Risk Factors” and elsewhere in our filing made with the Securities and Exchange Commission on the Form 10-Q on May 8, 2020. These forward-looking statements speak only as of the date hereof and should not be unduly relied upon. iRhythm disclaims any obligation to update these forward-looking statements.Contact InformationMedia Hannah Lock Hotwire for iRhythm Technologies Email: irhythmuk@hotwireglobal.comSaige Smith HighwirePR irhythm@highwirepr.comInvestors Leigh Salvo Gilmartin Group investors@irhythmtech.com
- GlobeNewswire
iRhythm Technologies to Present at the 18th Annual Morgan Stanley Global Healthcare Conference
SAN FRANCISCO, Sept. 01, 2020 (GLOBE NEWSWIRE) -- iRhythm Technologies, Inc. (NASDAQ: IRTC), a leading digital health care solutions company focused on the advancement of cardiac care, today announced the company will be participating in the upcoming 18th Annual Morgan Stanley Global Healthcare Conference. iRhythm’s management is scheduled to present on Tuesday, September 15, 2020 at 11:45 a.m. Eastern Time. Interested parties may access a live and archived webcast of the presentation on the “Investors” section of the company’s website at: www.irhythmtech.com.About iRhythm Technologies, Inc. iRhythm is a leading digital health care company redefining the way cardiac arrhythmias are clinically diagnosed. The company combines wearable biosensor devices worn for up to 14 days and cloud-based data analytics with powerful proprietary algorithms that distill data from millions of heartbeats into clinically actionable information. The company believes improvements in arrhythmia detection and characterization have the potential to change clinical management of patients.Investor Relations Contact Lynn Pieper Lewis or Leigh Salvo (415) 937-5404 investors@irhythmtech.com Media Contact Saige Smith (262) 289-7065 irhythm@highwirepr.com
- GlobeNewswire
Digital Transformation of Healthcare: CEO’s of ONEM, HCAT, DOCRF, IRTC, Discuss Telemedicine, Big Data, and Diagnostics
NEW YORK, Aug. 24, 2020 (GLOBE NEWSWIRE) -- Wall Street Reporter, the trusted name in financial news since 1843, has published reports on the latest comments and insights from CEO’s of Health Catalyst, Inc. (NASDAQ:HCAT), CloudMD (OTC: DOCRF), 1Life Healthcare, Inc. (NASDAQ:ONEM), and iRhythm Technologies, Inc. (NASDAQ:IRTC) Health Catalyst, Inc. (NASDAQ: HCAT) Dan Burton, CEO “Healthcare Analytics in the New Normal” Earnings Call Highlights: https://bit.ly/3aSo0z6CloudMD (OTC: DOCRF): "The Future of Telemedicine” Video: https://bit.ly/2Ycgv0J1Life Healthcare, Inc. (NASDAQ:ONEM), Amir Dan Rubin, CEO: “Transforming Healthcare for Consumers and Employers” Earnings Call Highlight: https://bit.ly/3hvOObaiRhythm Technologies, Inc. (NASDAQ: IRTC) CEO, Kevin King: “Driving the Standard of Care in Cardiac Arrhythmia Diagnostics & Management” Earnings Call Highlights:https://bit.ly/2CXGdikHighlights of CEO comments from latest earnings calls and investor conferences:1Life Healthcare, Inc. (NASDAQ:ONEM), Amir Dan Rubin, CEO: “Transforming Healthcare for Consumers and Employers” “...Through our digitally and clinically interconnected system of healthcare, we have expanded our membership base by 25% year-over-year and grown new and existing employer and consumer relationships. We have extended our service offerings with billable scheduled remote visit, mindset behavioral health, COVID-19 screening and testing, and our One Medical Now national digital health employer solution. We have addressed ongoing physical wellness and mental health needs, and continued extending care to pediatrics and family members. All the while we have delivered value-based results and saving to employers…We ended the quarter with 475,000 members, growing 25% year-over-year and adding 20,000 members in Q2. Continuing our strong momentum from Q1, we have added more than 50,000 members in our first half this year. These figures represent the strongest Q2 and first half membership adds in our history. We delivered net revenue of $78 million for this quarter, up 18% year-over-year….We are transforming healthcare for multiple key stakeholders; consumers, employers, providers, and health network.”“...We have also extended our 24/7 on-demand virtual service and launched it as a new offering in geographies where we don't yet have a physical footprint. This new offering, which we call One Medical Now has seen strong interest from national employers who look to us to provide the One Medical service experience to more of their employees while reducing their total healthcare costs through our bundled digital health and salaried provider model... “1Life Healthcare, Inc. (NASDAQ:ONEM) Earnings Call Highlights Available at: https://bit.ly/3hvOObaCloudMD (OTC: DOCRF): "The Future of Telemedicine" CloudMD (OTC: DOCRF) (TSX.V:DOC) CEO Dr. Essam Hamza, M.D. was recently interviewed by Wall Street Reporter and shared how CloudMD is addressing a multi-billion dollar market opportunity by digitizing the delivery of healthcare - providing patients access to all points of their care from their phone, tablet or desktop computer.Click here to watch DOCRF video interview: https://bit.ly/2Ycgv0JAugust 26: CloudMD is presenting at Wall Street Reporter’s NEXT SUPER STOCK livestream investor conference 8/26. Click here to join: https://bit.ly/2PX0SpHCloudMD offers SaaS based health technology solutions to medical clinics and healthcare providers across North America and has developed proprietary technology that delivers quality healthcare through the combination of connected primary care clinics, telemedicine, and artificial intelligence (AI). CloudMD currently provides service to a combined ecosystem of 376 clinics, over 3000 licensed practitioners and almost 3 million patient charts across its servers.Latest DOCRF News: August 24 - DOCRF is acquiring Re:Function Health Group Inc., a profitable seven location rehabilitation clinic network with C$5.8 million annual revenue. This acquisition represents a significant addition to the depth and spectrum of healthcare services provided by the CloudMD platform. With Re:Function, CloudMD’s network will include 14 clinics servicing approximately 500,000 patients. The acquisition is mutually important in the shared vision to disrupt the current healthcare delivery system and to provide continuity of care across multiple verticals to ensure exceptional patient care. CloudMD will integrate its telemedicine solutions throughout the clinics, layering on additional allied health and specialist functions to the platform. CloudMD’s registered users will now have access to primary care Doctors, specialists, and a network of mental, occupational and physical health specialists. The Re:Function team also gives CloudMD’s network of primary care physicians options to give patients referrals to extended care.August 13 - DOCRF is acquiring majority interest in West Mississauga Medical Clinic, a comprehensive family medicine and specialist medical clinic serving over 100,000 patients, securing footprint in Ontario with cash flow positive clinic, with revenue of C$1.8 million in 2019.August 6 - DOCRF continues US expansion with an acquisition of a chronic care medical clinic in Mississippi, as a part of its broader strategy for entering the U.S. market with its comprehensive suite of telehealth products. This clinic will power a network of telehealth powered satellite clinics covering large areas of underserviced areas across the U.S.CloudMD (OTC: DOCRF) is presenting at Wall Street Reporter’s NEXT SUPER STOCK livestream investor conference on August 26. Click here to join: https://bit.ly/2PX0SpHHealth Catalyst, Inc. (NASDAQ: HCAT) Dan Burton, CEO “Healthcare Analytics in the New Normal”. “..We cannot think of any event in recent history that has galvanized the awareness and importance of data and analytics more than COVID-19; and thus we believe it will serve as a meaningful tailwind in the industry's adoption of data and analytics. At the health system level, we are seeing COVID-19 highlighting the need for a commercial grade data and analytics solution to replace patchwork homegrown systems. I would also share that we are seeing the potential for meaningful government investment in healthcare data and analytics infrastructure modernization over time. Lastly, I'd share that we anticipate a meaningful long-term impact on our life sciences business as we leverage one of the largest clinically rich repositories of health data in the world for real world insights... ““...We are thrilled to welcome the talented and diverse Healthfinch to Health Catalyst, further enabling our mission to be the catalyst for massive, measurable data informed healthcare improvement... Some comments on our announcement today of our definitive agreement to acquire Vitalware: Vitalware offers a revenue workflow optimization, an analytics SaaS technology solution to healthcare providers.Vitalware provides us with another analytics application offering us a strategic anchor technology in the revenue space, expanding our CFO value proposition. Vitalware's flagship offering is a best-in-class Chargemaster Solution that solves a complex regulatory and billing function needed by all health systems. Additionally, Vitalware brings to bear a meaningful upsell opportunity with new product suites in revenue integrity and price transparency...Vitalware's compelling financial profile, includes greater than 90% recurring technology revenue with approximately $19 million in 2020 estimated standalone full-year recurring revenue and a 20-plus percent annual historical growth rate. Vitalware has approximately 75% gross margins and is adjusted EBITDA breakeven... “Health Catalyst (NASDAQ:HCAT) Earnings Call Highlights Available at: https://bit.ly/3aSo0z6iRhythm Technologies, Inc. (NASDAQ:IRTC) CEO, Kevin King: “Driving the Standard of Care in Cardiac Arrhythmia Diagnostics & Management” “...While COVID-19 suppressed the overall market in the second quarter, we believe iRhythm increased its share of the market as measured by our success in 3 areas. First, compared to legacy Holter monitoring services, our clinically superior digital platform was proven to be well suited to deliver services in a virtual environment. Our single-use ZIO devices are patient-friendly and eliminate the need for cleaning of equipment between uses. Second, our home enrollment service enabled by our digital platform was instrumental in maintaining the registration levels we experienced in the quarter. We expect it will remain an important component of many of our accounts workflows going forward. As we shared in early May, home enrollment represented over 50% of registrations for the month of April. As hospitals and physicians began resuming in-office patient visits, this percentage leveled out to just below 30% as we exited the quarter. We expect to remain at these levels for the foreseeable future, and believe this will be a key factor in ensuring continuity of patient care in the event of a continued ramp in COVID cases that leads to reduced in-office patient care…”“Lastly, ZIO AT demonstrated continued strong traction and meaningful growth over the first quarter of 2021 - over 2020. Our single platform solution continues to resonate with our customers as they put high value in streamlining workflows across their cardiac monitoring needs. The experience that our customers have with ZIO XT and the high confidence of familiarity they have with our service and platform has benefited ZIO AT adoption...Less than a year into the full market launch of ZIO AT, we're very pleased with the adoption to date. We are increasingly confident that we can continue to expand into the MCT market and take meaningful share.”“...While we're cautious on the outlook for the remainder of 2020 and would be hesitant to predict a fast recovery, we believe the future of iRhythm has never been brighter. There is a considerable potential for structural changes to how health care is delivered. And that will play to the strengths of our digital platform. We're focused on positioning iRhythm to continue to drive the standard of care in how cardiac arrhythmias are diagnosed and managed and delivering our ZIO Service to the millions.”iRhythm Technologies, Inc. (NASDAQ:IRTC) Earnings Call Highlights Available at:https://bit.ly/2CXGdikAbout Wall Street Reporter: Wall Street Reporter (Est. 1843) is the leading financial news provider, focused on giving investors direct access to CEO's of promising, publicly-traded companies, and market experts. www.WallStreetReporter.comAbout Wall Street Reporter’s “Next Super Stock” conference: Wall Street Reporter's NEXT SUPER STOCK Live! conference is dedicated to featuring select companies that have near-term catalysts in place which can drive transformational growth (and stock appreciation) in the months ahead. Click here to join the next livestream: https://bit.ly/2PX0SpHCONTACT: WALL STREET REPORTER (212) 871-2057 ext 7 www.WallStreetReporter.com
